❗ Early bird Discount is Expiring Soon ❗ This Friday marks your last chance to take advantage of discounts of up to $1,100 for the 3rd Annual LNP Immunogenicity & Toxicity Summit. Join leaders from Moderna, BioNTech, Pfizer, AstraZeneca, AbbVie, Beam Therapeutics, Orna Therapeutics and lots more at the only event dedicated to advancing and improving prediction, characterization and monitoring of LNP safety. Secure your place ➡️ https://ter.li/z5g3uh
LNP Development Event Series
Biotechnology Research
Turbocharging Your Next Generation LNP End-to-End Development to Deliver Quality Products to Patients Faster
About us
A Community to Realize LNP Potential As LNP development advances, this group is dedicated to professionals optimizing LNP pipeline progression. Following the success of mRNA-LNP vaccines, we have come to realize this is only the tip of an iceberg. From complex payloads, CRISPR Cas9 gene editing and cell therapy to macromolecules, such as peptides, to applications in oncology, ophthalmology and chronic diseases, the potential of novel LNPs is tremendous. Stay at the forefront of lipid nanoparticles, and help drive the development of next generation pipeline through clinic to market with efficacy, quality and affordability in mind!
- Website
-
https://hansonwade.com/process-development-manufacturing-conferences/
External link for LNP Development Event Series
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
Updates
-
❗JUST LAUNCHED – The 3rd LNP Immunogenicity & Toxicity Summit 📈 Assess LNP toxicity while predicting and monitoring clinical safety to ensure regulatory compliance for vaccines, gene and cell therapies 💡Returning as the only forum solely dedicated to assessing non-clinical and clinical LNP safety risk, by optimizing in vitro and in vivo tools for prediction, dosing and route of administration, characterize the immune response, and nanoparticle design to assess and improve safety in vaccines, gene and cell therapies. 🔎 Join experts from Pfizer, AstraZeneca, Moderna, Eli Lilly and Company and Beam Therapeutics, as they dive deep into mechanisms of toxicity, optimal delivery strategy, PEG-lipid alternatives and in vitro prediction, to progress development of safer LNP-delivered therapeutics. Across the 3 days you will gain insights into: ✔ Non-clinical assessment of LNP safety, including in vitro and in vivo models to advance prediction and risk assessment ✔ Case studies showcasing clinical data and immune-monitoring, as well as next-generation LNPs with optimal safety profiles ✔ Discussions on current regulatory guidelines, to support submissions and filings ✔ Solutions to control anti-PEG reactions, and refined LNP design to prevent immunogenic reactions ✔ Strategies to improve delivery, dosing and routes of administration to enhance specificity and mitigate adverse effects View the full program here: https://ter.li/r7xq78 The LNP team hope to see you in Boston this December!
-
-
LNP Development Event Series reposted this
❗BRAND NEW AGENDA – The 2nd LNP Characterization & Analytical Development Summit 📈 Revolutionizing Your LNP Drug Product Quality, Safety, Efficacy & Regulatory Compliance 💡 With resources tightened in parallel to regulatory scrutiny growing, the need for advanced analytical strategy has never been more pressing, to create bulletproof regulatory submissions. Diversity of formulations has spread excitement across the LNP field, however this brings more complex challenges when seeking thorough characterization data packages to advance from phase to phase. 🔎 Lipid nanoparticle professionals with expertise in characterization, analytical development, quality, regulatory and more have committed their time to the 2nd LNP Characterization & Analytical Development Summit to reevaluate their strategy as 2024 closes to hit the ground running in 2025. Some of the challenges addressed across the 3 days includes: 🔸 Focus in on the latest strategies to comprehensively characterize structural properties of complex lipid nanoparticles, including both static and dynamic properties to create an all-encompassing characterization profile of your LNP with NeoVac 🔸 Maximize translatability through seamless transition from in vitro to in vivo assay development to ensure efficiency of phase to phase development with Moderna 🔸 Manage the diverse interactions with LNP components and the payload, indicating the endosomal release outcomes to evolve with the increasingly complex drug products with Prime Medicine, Inc. 🔸 Develop a robust potency assay to reflect the mechanisms of action and total functionality of the LNP with Tessera Therapeutics View the full program here – https://ter.li/22norl For more information, please feel free to drop me a message and I would be more than happy to help. The LNP team hope to see you in Boston this November! Kieran Crewe Stephanie N. Clementine Aston #lnp #nanoparticle #drugdelivery #lipid #liposome #mrna #crispr #geneediting #nonviral
-
-
LNP Development Event Series reposted this
❗BRAND NEW AGENDA – The 2nd LNP Characterization & Analytical Development Summit 📈 Revolutionizing Your LNP Drug Product Quality, Safety, Efficacy & Regulatory Compliance 💡 With resources tightened in parallel to regulatory scrutiny growing, the need for advanced analytical strategy has never been more pressing, to create bulletproof regulatory submissions. Diversity of formulations has spread excitement across the LNP field, however this brings more complex challenges when seeking thorough characterization data packages to advance from phase to phase. 🔎 Lipid nanoparticle professionals with expertise in characterization, analytical development, quality, regulatory and more have committed their time to the 2nd LNP Characterization & Analytical Development Summit to reevaluate their strategy as 2024 closes to hit the ground running in 2025. Some of the challenges addressed across the 3 days includes: 🔸 Focus in on the latest strategies to comprehensively characterize structural properties of complex lipid nanoparticles, including both static and dynamic properties to create an all-encompassing characterization profile of your LNP with NeoVac 🔸 Maximize translatability through seamless transition from in vitro to in vivo assay development to ensure efficiency of phase to phase development with Moderna 🔸 Manage the diverse interactions with LNP components and the payload, indicating the endosomal release outcomes to evolve with the increasingly complex drug products with Prime Medicine, Inc. 🔸 Develop a robust potency assay to reflect the mechanisms of action and total functionality of the LNP with Tessera Therapeutics View the full program here – https://ter.li/22norl For more information, please feel free to drop me a message and I would be more than happy to help. The LNP team hope to see you in Boston this November! Kieran Crewe Stephanie N. Clementine Aston #lnp #nanoparticle #drugdelivery #lipid #liposome #mrna #crispr #geneediting #nonviral
-
-
🔦 Speaker Spotlight 🔦 Join Kinkini Roy, PhD and 80+ LNP experts to discuss critical strategies to develop stable, safe and site specific LNP drug products at the 3rd Lipid Nanoparticles Development Europe Summit (24-26 September, Berlin). Take a look at the agenda: https://ter.li/1dmn5 We caught up with Kinkini Roy, PhD recently, who told us how excited they are to be presenting their work alongside Sandipan Dawn, PhD in an exclusive deep-dive workshop titled ”Exploring the Rise of LNP Alternative Drug Delivery Systems”. In this hands-on session, they will compare the challenges faced with LNPs alongside polymeric systems, pinpointing translatable learnings to take forward. See full details of their session: https://ter.li/1dmn5s Unite with these industry leaders at the ultimate end-to-end LNP development discussion, to accelerate the clinical development of lipid nanoparticles and advance the therapeutic potential for mRNA, siRNA, CRISPR, cell therapy and lots more. #LipidNanoparticles #DrugDevelopment #LNP #Therapeutics #mRNA #siRNA #CRISPR #CellTherapy #Pharma #Biotech #Innovation
-
-
Want to be the next multi-million dollar investment? Brand-new biotech Exsilio Therapeutics launched with a huge $82 million investment last week dedicated to genomic medicine, including LNP delivery. Leverage this exciting landscape by joining the 3rd Lipid Nanoparticles Development Europe Summit in Berlin this September, and delve into open discussions and collaborations with our extensive LNP community. Take a look at the agenda: https://ter.li/h6915t What's more, our exclusive early bird savings are ending THIS Friday! Register now to save your seat at the heart of innovative LNP development: https://ter.li/lhxdqc #lnp #nanoparticle #drugdelivery #nonviral #mrna
-
-
BRAND NEW Speakers Alert! With the latest data and brand new speakers for 2024, the 3rd Lipid Nanoparticles Development Europe Summit in Berlin this September is providing the most up-to-date insights into LNP development and innovation. See the full speaker list: https://ter.li/d2pkqu Gain the answers to all your LNP questions from Bayer, CureVac, Pantherna Therapeutics GmbH, Ethris, Insmed Incorporated and more! Check out the agenda: https://ter.li/d2pkqu
-
-
Exciting to see one of our expert speakers Rongjun Chen and their team from Imperial College London partnering with GSK on a new collaboration to eradicate the expensive cold-chain storage process of RNA vaccines. Hear from Rongjun and 20+ other incredible speakers at the 3rd Lipid Nanoparticles Development Europe Summit this September in Berlin. Check out the full speaker list: https://ter.li/ij1v5w https://lnkd.in/ezmifQAZ
Our partnership with GSK to eliminate costly cold-chain storage of RNA vaccines has now been announced. Our patented, ground-breaking formulations have shown remarkable promise in protecting RNA-based vaccines and therapeutics and carrying them more effectively into cells. These formulations can enhance stability even at tropical temperatures and substantially reduce the dosage required for treatment. This partnership with GSK signifies a pivotal moment in our journey to unlock the full potential of RNA-based vaccines and therapeutics. We are thrilled to embark on this validation study, confident that our innovative formulations will pave the way for safer, more effective and affordable treatments against a range of diseases. The patented technologies have stemmed from the Future Vaccine Manufacturing Research Hub at Imperial College London, funded by the Department of Health and Social Care using UK Aid funding and managed by the Engineering and Physical Sciences Research Council (EPSRC). Very nice collaboration through the Hub between Professor Robin Shattock's research group in the Department of Infectious Diseases and my research group in the Department of Chemical Engineering. Many thanks to the Industry Partnerships and Commercialisation team/Enterprise, especially Valeska Gonzalez and James Chan, and the Contracts team in the Faculty of Engineering, Imperial College London for their endless support.
-
Have you heard about the revolutionary partnership between CordenPharma and Certest? Teaming up to add ionisable lipids into their LNP formulations, they're advancing the commercialisation of xRNA/xDNA. 📈 Stay ahead of the LNP curve by joining us at the 3rd Lipid Nanoparticles Development Europe Summit, the only industry-focused LNP summit in Europe. Check out the newly-released agenda: https://ter.li/mp19m3 Unite with 100+ LNP discovery, formulation, characterisation, and manufacturing experts this September to learn and advance your clinical progress. 🚨 Even better, register by midnight this Friday to save €1,100! https://ter.li/iuxakw
-
-
📢 BRAND NEW AGENDA RELEASE 📢 Fancy joining the LNP community in Berlin this September?
I am thrilled to announce the launch of the 3rd Lipid Nanoparticles Development Summit Europe, taking place from 24-26 September 2024 in Berlin, Germany. With LNPs continuing to dominate the conversation in the drug delivery world, join us at the only industry-focused summit in Europe to break the mould and discover the future of LNPs. 🔗 Learn more and explore the 3-day agenda here: https://ter.li/bpmek0 Unite with industry leaders to: 🔸 Unpick the structural complexities of lipid nanoparticles with Ethris 🔸 Drive pre-clinical research with advanced translatability with the Children's Hospital of Philadelphia 🔸 Ensure regulatory compliance with Bayer Develop LNPs with unmatched process efficiency with GSK Join your peers this September to spearhead the revolution of LNPs, leading the way for safe, stable, and site-specific drug delivery and propelling your pipelines into 2024 and beyond. 🚀 Learn more here: https://ter.li/bpmek0 Please reach out with any questions or comments about our brand new agenda. #LipidNanoparticles #LNP #DrugDelivery #Pharma #Biotech #Summit #Innovation Adam Mayar Bonnie Glendinning Emily Semmens
-